<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Current HIV Research</journal-id><journal-title-group><journal-title xml:lang="en">Current HIV Research</journal-title><trans-title-group xml:lang="ru"><trans-title>Current HIV Research</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1570-162X</issn><issn publication-format="electronic">1873-4251</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">644143</article-id><article-id pub-id-type="doi">10.2174/011570162X308550240821074309</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A Step Towards Optimization of Amide-Linked Coumarin Pharmacophore: As an Anti-HIV Agent</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Joshi</surname><given-names>Harish</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Vikas</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Purohit</surname><given-names>Priyank</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Pandey</surname><given-names>Indra</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Joshi</surname><given-names>Gaurav</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff id="aff1"><institution>Department of Chemistry, Graphic Era Deemed to be University</institution></aff><aff id="aff2"><institution>Department of Chemistry, Uttarakhand Technical University</institution></aff><aff id="aff3"><institution>School of Pharmacy, Graphic Era Hill University</institution></aff><aff id="aff4"><institution>Department of Chemistry Uttarakhand Technical University, Uttarakhand Technical University</institution></aff><aff id="aff5"><institution>Department of Pharmaceutical Sciences, HNBGU, (Central University)</institution></aff><pub-date date-type="pub" iso-8601-date="2024-05-01" publication-format="electronic"><day>01</day><month>05</month><year>2024</year></pub-date><volume>22</volume><issue>5</issue><issue-title xml:lang="ru"/><fpage>279</fpage><lpage>289</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/1570-162X/article/view/644143">https://journals.eco-vector.com/1570-162X/article/view/644143</self-uri><abstract xml:lang="en"><p>The aim of the present investigation is to identify effective anti-HIV drugs through the in-silico virtual screening of the coumarin pharmacophore with or without substituents. Virtual screening started with target identification through computation docking and interactions, binding affinity through molecular dynamics, and the ADMET profile through the use of various enzymes. The target study suggests that the target is involved in various stages of HIV replication and in determining the ways in which non-nucleoside reverse transcriptase inhibitors (RTIs) influence it. The interaction pattern and simulation study conclude the specific affinity of coumarin pharmacophore to the HIV's reverse transcriptase enzyme, especially 3HVT. Moreover, the amide linkage worked as a synergistic bridge to provide more interaction to the pharmacophore. The initial results led to the determination of 83 virtual amide-like molecules, which were screened through docking and MD studies (100 ns) on the best-suited enzyme HIV's reverse transcriptase enzyme, such as PDB ID "3HVT". The virtual screening study revealed the high affinity of compounds 7d and 7e with the lowest IC<sub>50</sub> values of 0.729 and 0.658 µM; moreover, their metabolism pattern study, toxicity, and QED values in a range of 0.31-0.40 support a good drug candidate. The two compounds were also synthesized and characterized for future in vitro and in vivo studies. The in silico-based descriptor of compounds 7d and 7e indicates the potential future and provides the best two molecules and their synthetic route for the development of a more effective drug to combat HIV/AIDS epidemics.</p></abstract><kwd-group xml:lang="en"><kwd>Reverse transcriptase inhibitors (RTI)</kwd><kwd>QSAR</kwd><kwd>HIV integrase inhibitors</kwd><kwd>coumarins</kwd><kwd>protease inhibitors (PI)</kwd><kwd>HIV/AIDS.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Coffin J, Haase A, Levy JA, et al. Human immunodeficiency viruses. Science 1986; 232(4751): 697-7. doi: 10.1126/science.3008335 PMID: 3008335</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kallings LO. The first postmodern pandemic: 25 years of HIV/AIDS. J Intern Med 2008; 263(3): 218-43. doi: 10.1111/j.1365-2796.2007.01910.x PMID: 18205765</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>van Schalkwyk C, Mahy M, Johnson LF, Imai-Eaton JW. Updated data and methods for the 2023 UNAIDS HIV estimates. J Acquir Immune Defic Syndr 2024; 95(1S): e1-4. doi: 10.1097/QAI.0000000000003344 PMID: 38180734</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV‐1 and HIV‐2 infection: Lessons for viral immunopathogenesis. Rev Med Virol 2013; 23(4): 221-40. doi: 10.1002/rmv.1739 PMID: 23444290</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312(5996): 763-7. doi: 10.1038/312763a0 PMID: 6096719</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Singh SK, Siddhanta A. Whether HIV discordance among couples is getting altered due to the changing discourse of the HIV epidemic in India? Evidence from two rounds of national Family Health survey. J Health Manag 2023; 25(2): 263-71. doi: 10.1177/09720634231175577</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pachuau LN, Tannous C, Chawngthu RL, Agho KE. HIV and its associated factors among people who inject drugs in Mizoram, Northeast India. PLoS One 2023; 18(5): e0286009. doi: 10.1371/journal.pone.0286009 PMID: 37216389</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 19902015: A systematic review, global survey, and trend analysis. Lancet Infect Dis 2019; 19(2): 143-55. doi: 10.1016/S1473-3099(18)30647-9 PMID: 30509777</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Basoulis D, Mastrogianni E, Voutsinas PM, Psichogiou M. HIV and COVID-19 co-infection: Epidemiology, clinical characteristics, and treatment. Viruses 2023; 15(2): 577. doi: 10.3390/v15020577 PMID: 36851791</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mittal RK, Aggarwal M, Khatana K, Purohit P. Quinoline: Synthesis to application. Med Chem 2022; 19(1): 31-46. PMID: 35240965</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mittal RK, Purohit P. Quinoline-3-carboxylic acids: A step toward highly selective antiproliferative agent. Anticancer Agents Med Chem 2021; 21(13): 1708-16.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Jadhavar PS. Sustainable approaches towards the synthesis of quinoxalines. Green Chem Synth Bioact Heterocycl 2014; 2014: 37-67. doi: 10.1007/978-81-322-1850-0_2</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>McKee TC, Covington CD, Fuller RW, et al. Pyranocoumarins from tropical species of the genus Calophyllum: A chemotaxonomic study of extracts in the National Cancer Institute collection. J Nat Prod 1998; 61(10): 1252-6. doi: 10.1021/np980140a PMID: 9784162</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Buckheit RW Jr, White EL, Fliakas-Boltz V, et al. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 1999; 43(8): 1827-34. doi: 10.1128/AAC.43.8.1827 PMID: 10428899</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Upadhyay RK. Anti-HIV natural products from medicinal plants: A review. Int J Green Pharm 2023; 17(1)</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Huang L, Kashiwada Y, Cosentino LM, Fan S, Lee K-H. 3′,4′-Di-o-(−)-camphanoyl-(+)-ciskhellactone and related compounds: A. new class of potent anti-HIV agents. Bioorg Med Chem Lett 1994; 4(4): 593-8. doi: 10.1016/S0960-894X(01)80161-X</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Yu D, Suzuki M, Xie L, Morris-Natschke SL, Lee KH. Recent progress in the development of coumarin derivatives as potent anti‐HIV agents. Med Res Rev 2003; 23(3): 322-45. doi: 10.1002/med.10034 PMID: 12647313</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Leonard JT, Roy K. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur J Med Chem 2008; 43(1): 81-92. doi: 10.1016/j.ejmech.2007.02.021 PMID: 17452064</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Beyer A, Lawtrakul L, Pungpo P, Wolschann P. Structural aspects of non-nucleoside HIV-1 reverse transcriptase inhibition. Curr Computeraided Drug Des 2007; 3(2): 87-100. doi: 10.2174/157340907780809507</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Işık A, Çevik UA, Celik I, et al. Synthesis, characterization, molecular docking, dynamics simulations, and in silico absorption, distribution, metabolism, and excretion (ADME) studies of new thiazolylhydrazone derivatives as butyrylcholinesterase inhibitors. Z Naturforsch C J Biosci 2022; 77(11-12): 447-57. doi: 10.1515/znc-2021-0316 PMID: 35599239</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Işık A, Acar Çevik U, Karayel A, et al. Synthesis, DFT calculations, in silico studies, and antimicrobial evaluation of benzimidazole-thiadiazole derivatives. ACS Omega 2024; 9(16): 18469-79. doi: 10.1021/acsomega.4c00543 PMID: 38680334</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Fuchs DI, Serio LD, Balaji S, Sprenger KG. Investigating how HIV-1 antiretrovirals differentially behave as substrates and inhibitors of P-glycoprotein via molecular dynamics simulations. Comput Struct Biotechnol J 2024; 23: 2669-79. doi: 10.1016/j.csbj.2024.06.025 PMID: 39027651</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kumar V, Pandey IP, Jain J, Tripathi RB. One step towards: The synthesis of optimized coumarin derivatives as an anti-HIV Agent. Indian J Pharmaceut Educat Res 2019; 53(4s): s624-9. doi: 10.5530/ijper.53.4s.158</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Maheswara M, Siddaiah V, Damu GLV, Rao YK, Rao CV. A solvent-free synthesis of coumarins via Pechmann condensation using heterogeneous catalyst. J Mol Catal Chem 2006; 255(1-2): 49-52. doi: 10.1016/j.molcata.2006.03.051</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Dittmer DC, Li Q, Avilov DV. Synthesis of coumarins, 4-hydroxycoumarins, and 4-hydroxyquinolinones by tellurium-triggered cyclizations. J Org Chem 2005; 70(12): 4682-6. doi: 10.1021/jo050070u PMID: 15932305</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Khalymbadzha IA, Fatykhov RF, Butorin II, et al. bioinspired pyrano2,3-fchromen-8-ones: Ring C-opened analogues of calanolide A: Synthesis and anti-HIV-1 evaluation. Biomimetics 2024; 9(1): 44. doi: 10.3390/biomimetics9010044 PMID: 38248618</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Zeki NM, Mustafa YF. Coumarin hybrids: a sighting of their roles in drug targeting. Chem Zvesti 2024; 78(10): 5753-72. doi: 10.1007/s11696-024-03498-z</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Doucet C, Pochet L, Thierry N, Pirotte B, Delarge J, Reboud-Ravaux M. 6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase. J Med Chem 1999; 42(20): 4161-71. doi: 10.1021/jm990070k PMID: 10514286</mixed-citation></ref></ref-list></back></article>
